Education is needed at all levels of the health care system to aid providers in making the most informed possible decisions in caring for this patient population.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic co

The prevalence of genetic predisposition to cancer is greater than initially appreciated. Due to the increase in multigene testing and the evidence-base surrounding genes and hereditary syndromes associated with cancer, the recommendations in the NCCN Guidelines for Genetic/Familial High-Risk Assessment have expanded and adapted accordingly.
Knowledge of specific germline mutations and their unique characteristics helps nurses to properly educate patients on surveillance plans and targeted systemic therapy treatment options, improving compliance, efficacy of cancer treatment and morbidity.
It is critical for individuals with a family history of Lynch syndrome to have genetic counseling and testing in order to identify those who are at risk and implement appropriate screening, surveillance, and risk-reduction strategies based on the individual’s risk profile. Clinicians need to recognize the role of genetic testing and counseling and the importance of a personalized and patient-centric approach to care of individuals with a hereditary cancer syndrome.
Education is needed at all levels of the health care system to aid providers in making the most informed possible decisions in caring for this patient population.
These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.
The field of cancer genetics has implications for all aspects of cancer management of individuals with hereditary or familial cancers, including prevention, screening, and treatment. A management plan based on genetic test results should only be developed for identified pathogenic or likely pathogenic variants that are clinically actionable.
These NCCN Guidelines Insights focus on familial adenomatous polyposis (FAP)/attenuated familial adenomatous polyposis (AFAP) syndrome and considerations for management of duodenal neoplasia.
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers.
Subscribe to RSS - Genetic/Familial High-Risk Assessment